Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 204

1.

Myocardial calcification in a patient with B-lymphoblastic leukemia accompanied by tumor lysis syndrome.

Usui G, Hashimoto H, Uchibori Y, Usuki K, Horiuchi H, Morikawa T.

Cardiovasc Pathol. 2019 Aug 7;43:107146. doi: 10.1016/j.carpath.2019.07.005. [Epub ahead of print]

PMID:
31499334
2.

Efficacy and safety of quizartinib in Japanese patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia in an open-label, phase 2 study.

Takahashi T, Usuki K, Matsue K, Ohno H, Sakura T, Imanaka R, Murakami M, Ohwada S, Takagi T, Sakajiri S.

Int J Hematol. 2019 Aug 31. doi: 10.1007/s12185-019-02727-6. [Epub ahead of print]

PMID:
31473943
3.

Significance of FLT3-tyrosine kinase domain mutation as a prognostic factor for acute myeloid leukemia.

Sakaguchi M, Yamaguchi H, Kuboyama M, Najima Y, Usuki K, Ueki T, Oh I, Mori S, Kawata E, Uoshima N, Kobayashi Y, Kako S, Tajika K, Shono K, Kayamori K, Hagihara M, Kanda J, Uchiyama H, Kuroda J, Uchida N, Kubota Y, Kimura S, Kurosawa S, Date K, Nakajima N, Marumo A, Omori I, Fujiwara Y, Terada K, Yui S, Wakita S, Arai K, Kitano T, Kakihana K, Kanda Y, Ohashi K, Fukuda T, Inokuchi K.

Int J Hematol. 2019 Aug 20. doi: 10.1007/s12185-019-02720-z. [Epub ahead of print]

PMID:
31432396
4.

Serum ferritin levels at diagnosis predict prognosis in patients with low blast count myelodysplastic syndromes.

Kawabata H, Usuki K, Shindo-Ueda M, Kanda J, Tohyama K, Matsuda A, Araseki K, Hata T, Suzuki T, Kayano H, Shimbo K, Chiba S, Ishikawa T, Arima N, Nohgawa M, Miyazaki Y, Kurokawa M, Arai S, Mitani K, Takaori-Kondo A; Japanese National Research Group on Idiopathic Bone Marrow Failure Syndromes.

Int J Hematol. 2019 Jul 29. doi: 10.1007/s12185-019-02710-1. [Epub ahead of print]

PMID:
31359362
5.

Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study.

Usuki K, Handa H, Choi I, Yamauchi T, Iida H, Hata T, Ohwada S, Okudaira N, Nakamura K, Sakajiri S.

Int J Hematol. 2019 Jul 29. doi: 10.1007/s12185-019-02709-8. [Epub ahead of print]

PMID:
31359361
6.

Increased SLAMF7high monocytes in myelofibrosis patients harboring JAK2V617F provide a therapeutic target of elotuzumab.

Maekawa T, Kato S, Kawamura T, Takada K, Sone T, Ogata H, Saito K, Izumi T, Nagao S, Takano K, Okada Y, Tachi N, Teramoto M, Horiuchi T, Hikota-Saga R, Endo-Umeda K, Uno S, Osawa Y, Kobayashi A, Kobayashi S, Sato K, Hashimoto M, Suzu S, Usuki K, Morishita S, Araki M, Makishima M, Komatsu N, Kimura F.

Blood. 2019 Sep 5;134(10):814-825. doi: 10.1182/blood.2019000051. Epub 2019 Jul 3.

PMID:
31270105
7.

Prospective randomized trial comparing two doses of rabbit anti-thymocyte globulin in patients with severe aplastic anaemia.

Narita A, Zhu X, Muramatsu H, Chen X, Guo Y, Yang W, Zhang J, Liu F, Jang JH, Kook H, Kim H, Usuki K, Yamazaki H, Takahashi Y, Nakao S, Wook Lee J, Kojima S; Aplastic Anaemia Working Party of the Asia-Pacific Blood, Marrow Transplantation Group.

Br J Haematol. 2019 Jun 17. doi: 10.1111/bjh.16055. [Epub ahead of print]

PMID:
31206607
8.

Prognostic impact of cytogenetic abnormalities in adult patients with Philadelphia chromosome-negative ALL who underwent an allogeneic transplant.

Shimizu H, Doki N, Kanamori H, Sakura T, Mori T, Machida S, Takahashi S, Ohwada C, Fujisawa S, Yano S, Hagihara M, Kanda Y, Onoda M, Gotoh M, Kako S, Taguchi J, Usuki K, Kawai N, Aotsuka N, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT).

Bone Marrow Transplant. 2019 Jun 11. doi: 10.1038/s41409-019-0585-2. [Epub ahead of print]

PMID:
31186516
9.

Hematologic recovery induced by eltrombopag in Japanese patients with aplastic anemia refractory or intolerant to immunosuppressive therapy.

Yamazaki H, Ohta K, Iida H, Imada K, Obara N, Tokumine Y, Tomiyama Y, Usuki K, Imajo K, Miyamura K, Sasaki O, Fanghong Z, Hattori T, Tajima T, Matsuda A, Nakao S.

Int J Hematol. 2019 Aug;110(2):187-196. doi: 10.1007/s12185-019-02683-1. Epub 2019 Jun 10.

PMID:
31183813
10.

Prognostic index for patients with relapsed or refractory acute myeloid leukemia who underwent hematopoietic cell transplantation: a KSGCT multicenter analysis.

Tachibana T, Kanda J, Ishizaki T, Najima Y, Tanaka M, Doki N, Fujiwara SI, Kimura SI, Onizuka M, Takahashi S, Saito T, Mori T, Fujisawa S, Sakaida E, Matsumoto K, Aotsuka N, Goto M, Watanabe R, Shono K, Usuki K, Tsukada N, Kanamori H, Kanda Y, Okamoto S; Kanto Study; Group for Cell Therapy (KSGCT).

Leukemia. 2019 May 30. doi: 10.1038/s41375-019-0494-9. [Epub ahead of print]

PMID:
31147621
11.

Efficacy and safety of oral deferasirox treatment for transfusional iron overload in pure red cell aplasia patients after allogeneic stem cell transplantation.

Shimizu R, Takeuchi M, Sakaida E, Ohwada C, Toyosaki M, Machida S, Onizuka M, Shono K, Onoda M, Saito T, Yano S, Tanaka M, Fujisawa S, Mori T, Usuki K, Takahashi S, Kanamori H, Nakaseko C, Okamoto S.

Ann Hematol. 2019 Jul;98(7):1781-1783. doi: 10.1007/s00277-019-03717-8. Epub 2019 May 22. No abstract available.

PMID:
31119366
12.

Short course radiation therapy for rectal cancer in the elderly: can radical surgery be avoided?

Cummings MA, Usuki KY, Fleming FJ, Tejani MA, Katz AW.

J Gastrointest Oncol. 2019 Apr;10(2):357-361. doi: 10.21037/jgo.2018.09.05.

13.

Amikacin Pharmacokinetics in Terminal Stage of Hematological Malignancy.

Nakayama H, Suzuki M, Usuki K, Kato T.

Ther Drug Monit. 2019 Aug;41(4):533-537. doi: 10.1097/FTD.0000000000000621.

PMID:
30817701
14.

Escape hematopoiesis by donor-derived 6pLOH(+) hematopoietic stem cells in a marrow transplant recipient with late graft failure.

Hino T, Imi T, Hangaishi A, Kamoda Y, Iizuka H, Hirao M, Kida M, Tojo A, Nakao S, Usuki K.

Bone Marrow Transplant. 2019 Jul;54(7):1129-1132. doi: 10.1038/s41409-018-0420-1. Epub 2019 Jan 10. No abstract available.

PMID:
30631099
15.

Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial).

Fujisawa S, Ueda Y, Usuki K, Kobayashi H, Kondo E, Doki N, Nakao T, Kanda Y, Kosugi N, Kosugi H, Kumagai T, Harada H, Shikami M, Maeda Y, Sakura T, Inokuchi K, Saito A, Nawa Y, Ogasawara M, Nishida J, Kondo T, Yoshida C, Kuroda H, Tabe Y, Maeda Y, Imajo K, Kojima K, Morita S, Komukai S, Kawaguchi A, Sakamoto J, Kimura S.

Int J Clin Oncol. 2019 Apr;24(4):445-453. doi: 10.1007/s10147-018-1368-2. Epub 2018 Nov 12.

16.

Recurrent CCND3 mutations in MLL-rearranged acute myeloid leukemia.

Matsuo H, Yoshida K, Fukumura K, Nakatani K, Noguchi Y, Takasaki S, Noura M, Shiozawa Y, Shiraishi Y, Chiba K, Tanaka H, Okada A, Nannya Y, Takeda J, Ueno H, Shiba N, Yamato G, Handa H, Ono Y, Hiramoto N, Ishikawa T, Usuki K, Ishiyama K, Miyawaki S, Itonaga H, Miyazaki Y, Kawamura M, Yamaguchi H, Kiyokawa N, Tomizawa D, Taga T, Tawa A, Hayashi Y, Mano H, Miyano S, Kamikubo Y, Ogawa S, Adachi S.

Blood Adv. 2018 Nov 13;2(21):2879-2889. doi: 10.1182/bloodadvances.2018019398.

17.

Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia.

Sakaguchi M, Yamaguchi H, Najima Y, Usuki K, Ueki T, Oh I, Mori S, Kawata E, Uoshima N, Kobayashi Y, Kako S, Tajika K, Gomi S, Shono K, Kayamori K, Hagihara M, Kanda J, Uchiyama H, Kuroda J, Uchida N, Kubota Y, Kimura S, Kurosawa S, Nakajima N, Marumo A, Omori I, Fujiwara Y, Yui S, Wakita S, Arai K, Kitano T, Kakihana K, Kanda Y, Ohashi K, Fukuda T, Inokuchi K.

Blood Adv. 2018 Oct 23;2(20):2744-2754. doi: 10.1182/bloodadvances.2018020305.

18.

Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open-label phase 1 study.

Usuki K, Sakura T, Kobayashi Y, Miyamoto T, Iida H, Morita S, Bahceci E, Kaneko M, Kusano M, Yamada S, Takeshita S, Miyawaki S, Naoe T.

Cancer Sci. 2018 Oct;109(10):3235-3244. doi: 10.1111/cas.13749.

19.

R-High-CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY.

Ogura M, Yamamoto K, Morishima Y, Wakabayashi M, Tobinai K, Ando K, Uike N, Kurosawa M, Gomyo H, Taniwaki M, Nosaka K, Tsukamoto N, Shimoyama T, Fukuhara N, Yakushijin Y, Ohnishi K, Miyazaki K, Sawada K, Takayama N, Hanamura I, Nagai H, Kobayashi H, Usuki K, Kobayashi N, Ohyashiki K, Utsumi T, Kumagai K, Maruyama D, Ohmachi K, Matsuno Y, Nakamura S, Hotta T, Tsukasaki K; Japan Clinical Oncology Group- Lymphoma Study Group (JCOG-LSG).

Cancer Sci. 2018 Sep;109(9):2830-2840. doi: 10.1111/cas.13719. Epub 2018 Jul 28.

20.

Interobserver concordance of assessments of dysplasia and blast counts for the diagnosis of patients with cytopenia: From the Japanese central review study.

Matsuda A, Kawabata H, Tohyama K, Maeda T, Araseki K, Hata T, Suzuki T, Kayano H, Shimbo K, Usuki K, Chiba S, Ishikawa T, Arima N, Nohgawa M, Ohta A, Miyazaki Y, Nakao S, Ozawa K, Arai S, Kurokawa M, Mitani K, Takaori-Kondo A; Japanese National Research Group on Idiopathic Bone Marrow Failure Syndromes.

Leuk Res. 2018 Nov;74:137-143. doi: 10.1016/j.leukres.2018.06.003. Epub 2018 Jun 7.

PMID:
29914726
21.

Radiation-Induced Edema After Single-Fraction or Multifraction Stereotactic Radiosurgery for Meningioma: A Critical Review.

Milano MT, Sharma M, Soltys SG, Sahgal A, Usuki KY, Saenz JM, Grimm J, El Naqa I.

Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):344-357. doi: 10.1016/j.ijrobp.2018.03.026. Epub 2018 Mar 29.

PMID:
29726362
22.

Impact of Right-sided Primary Tumor Location Among Patients With Oligometastatic Colorectal Cancer Treated With Stereotactic Body Radiotherapy.

Bates JE, Choi G, Usuki KY, Katz AW, Milano MT.

Am J Clin Oncol. 2018 Dec;41(12):1172-1175. doi: 10.1097/COC.0000000000000445.

PMID:
29664795
23.

Usefulness of BCOR gene mutation as a prognostic factor in acute myeloid leukemia with intermediate cytogenetic prognosis.

Terada K, Yamaguchi H, Ueki T, Usuki K, Kobayashi Y, Tajika K, Gomi S, Kurosawa S, Saito R, Furuta Y, Miyadera K, Tokura T, Marumo A, Omori I, Sakaguchi M, Fujiwara Y, Yui S, Ryotokuji T, Arai K, Kitano T, Wakita S, Fukuda T, Inokuchi K.

Genes Chromosomes Cancer. 2018 Aug;57(8):401-408. doi: 10.1002/gcc.22542.

PMID:
29663558
24.

Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment.

Okada M, Imagawa J, Tanaka H, Nakamae H, Hino M, Murai K, Ishida Y, Kumagai T, Sato S, Ohashi K, Sakamaki H, Wakita H, Uoshima N, Nakagawa Y, Minami Y, Ogasawara M, Takeoka T, Akasaka H, Utsumi T, Uike N, Sato T, Ando S, Usuki K, Mizuta S, Hashino S, Nomura T, Shikami M, Fukutani H, Ohe Y, Kosugi H, Shibayama H, Maeda Y, Fukushima T, Yamazaki H, Tsubaki K, Kukita T, Adachi Y, Nataduka T, Sakoda H, Yokoyama H, Okamoto T, Shirasugi Y, Onishi Y, Nohgawa M, Yoshihara S, Morita S, Sakamoto J, Kimura S; DADI Trial Group, Japan.

Clin Lymphoma Myeloma Leuk. 2018 May;18(5):353-360.e1. doi: 10.1016/j.clml.2018.03.004. Epub 2018 Mar 15.

25.

[Successful treatment of large granular lymphocytic leukemia accompanied by refractory anemia with alemtuzumab].

Iijima K, Hirao M, Hino T, Kamoda Y, Iizuka H, Kida M, Hangaishi A, Usuki K.

Rinsho Ketsueki. 2017;58(12):2392-2396. doi: 10.11406/rinketsu.58.2392. Japanese.

PMID:
29332872
26.

Cytogenetic risk stratification may predict allogeneic hematopoietic stem cell transplantation outcomes for chronic myelomonocytic leukemia.

Motohashi K, Fujisawa S, Doki N, Kobayashi T, Mori T, Usuki K, Tanaka M, Fujiwara S, Kako S, Aoyama Y, Onoda M, Yano S, Gotoh M, Kanamori H, Takahashi S, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT).

Leuk Lymphoma. 2018 Jun;59(6):1332-1337. doi: 10.1080/10428194.2017.1387913. Epub 2017 Oct 16.

PMID:
29032731
27.

Full-length mutation search of the TP53 gene in acute myeloid leukemia has increased significance as a prognostic factor.

Terada K, Yamaguchi H, Ueki T, Usuki K, Kobayashi Y, Tajika K, Gomi S, Kurosawa S, Miyadera K, Tokura T, Omori I, Marumo A, Fujiwara Y, Yui S, Ryotokuji T, Osaki Y, Arai K, Kitano T, Kosaka F, Wakita S, Tamai H, Fukuda T, Inokuchi K.

Ann Hematol. 2018 Jan;97(1):51-61. doi: 10.1007/s00277-017-3143-2. Epub 2017 Oct 4.

PMID:
28980058
28.

Single-Fraction Radiosurgery Using Conservative Doses for Brain Metastases: Durable Responses in Select Primaries With Limited Toxicity.

Cummings M, Youn P, Bergsma DP, Usuki KY, Walter K, Sharma M, Okunieff P, Schell MC, Milano MT.

Neurosurgery. 2018 Sep 1;83(3):437-444. doi: 10.1093/neuros/nyx427.

PMID:
28945885
29.

Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study.

Takahashi N, Tauchi T, Kitamura K, Miyamura K, Saburi Y, Hatta Y, Miyata Y, Kobayashi S, Usuki K, Matsumura I, Minami Y, Usui N, Fukuda T, Takada S, Ishikawa M, Fujimaki K, Gomyo H, Sasaki O, Ohishi K, Miyake T, Imai K, Suzushima H, Mitsui H, Togitani K, Kiguchi T, Atsuta Y, Ohtake S, Ohnishi K, Kobayashi Y, Kiyoi H, Miyazaki Y, Naoe T; Japan Adult Leukemia Study Group.

Int J Hematol. 2018 Feb;107(2):185-193. doi: 10.1007/s12185-017-2334-x. Epub 2017 Sep 19.

PMID:
28929332
30.

A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study).

Kobayashi T, Nannya Y, Ichikawa M, Oritani K, Kanakura Y, Tomita A, Kiyoi H, Kobune M, Kato J, Kawabata H, Shindo M, Torimoto Y, Yonemura Y, Hanaoka N, Nakakuma H, Hasegawa D, Manabe A, Fujishima N, Fujii N, Tanimoto M, Morita Y, Matsuda A, Fujieda A, Katayama N, Ohashi H, Nagai H, Terada Y, Hino M, Sato K, Obara N, Chiba S, Usuki K, Ohta M, Imataki O, Uemura M, Takaku T, Komatsu N, Kitanaka A, Shimoda K, Watanabe K, Tohyama K, Takaori-Kondo A, Harigae H, Arai S, Miyazaki Y, Ozawa K, Kurokawa M; for National Research Group on Idiopathic Bone Marrow Failure Syndromes.

Am J Hematol. 2017 Dec;92(12):1324-1332. doi: 10.1002/ajh.24905. Epub 2017 Sep 28.

31.

D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations.

Yui S, Kurosawa S, Yamaguchi H, Kanamori H, Ueki T, Uoshima N, Mizuno I, Shono K, Usuki K, Chiba S, Nakamura Y, Yanada M, Kanda J, Tajika K, Gomi S, Fukunaga K, Wakita S, Ryotokuji T, Fukuda T, Inokuchi K.

Ann Hematol. 2017 Oct;96(10):1641-1652. doi: 10.1007/s00277-017-3074-y. Epub 2017 Jul 31.

PMID:
28762080
32.

SBRT for Hepatocellular Carcinoma: 8-Year Experience from a Regional Transplant Center.

Qiu H, Moravan MJ, Milano MT, Usuki KY, Katz AW.

J Gastrointest Cancer. 2018 Dec;49(4):463-469. doi: 10.1007/s12029-017-9990-1.

PMID:
28710606
33.

Targeting complete response with upfront bortezomib consolidation versus observation after the achievement of complete response following autologous transplantation for multiple myeloma (TUBA study).

Nakasone H, Terasako-Saito K, Hirano T, Wake A, Shimizu S, Kurita N, Yamazaki E, Usuki K, Akazawa K, Kanda J, Minauchi K, Yamamoto G, Tanimoto S, Kamoshita M, Yokoyama Y, Miyaoka E, Ota S, Kako S, Izutsu K, Kanda Y.

Hematol Oncol. 2018 Feb;36(1):202-209. doi: 10.1002/hon.2452. Epub 2017 Jul 6.

PMID:
28681529
34.

Validation of the revised International Prognostic Scoring System in patients with myelodysplastic syndrome in Japan: results from a prospective multicenter registry.

Kawabata H, Tohyama K, Matsuda A, Araseki K, Hata T, Suzuki T, Kayano H, Shimbo K, Zaike Y, Usuki K, Chiba S, Ishikawa T, Arima N, Nogawa M, Ohta A, Miyazaki Y, Mitani K, Ozawa K, Arai S, Kurokawa M, Takaori-Kondo A; Japanese National Research Group on Idiopathic Bone Marrow Failure Syndromes.

Int J Hematol. 2017 Sep;106(3):375-384. doi: 10.1007/s12185-017-2250-0. Epub 2017 May 11.

PMID:
28497239
35.

Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report.

Nakamae H, Fujisawa S, Ogura M, Uchida T, Onishi Y, Taniwaki M, Utsunomiya A, Matsue K, Takamatsu Y, Usuki K, Tanimoto M, Ishida Y, Ohashi K, Li L, Miyoshi M.

Int J Hematol. 2017 Jun;105(6):792-804. doi: 10.1007/s12185-017-2208-2. Epub 2017 Mar 24.

PMID:
28341918
36.

Efficacy of pomalidomide in a multiple myeloma patient requiring hemodialysis.

Kida M, Hirao M, Iizuka H, Hangaishi A, Usuki K.

Rinsho Ketsueki. 2016;57(11):2339-2344. Japanese.

PMID:
27941283
37.

Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan.

Ogura M, Ishizawa K, Maruyama D, Uike N, Ando K, Izutsu K, Terui Y, Imaizumi Y, Tsukasaki K, Suzuki K, Izumi T, Usuki K, Kinoshita T, Taniwaki M, Uoshima N, Suzumiya J, Kurosawa M, Nagai H, Uchida T, Fukuhara N, Choi I, Ohmachi K, Yamamoto G, Tobinai K; Japanese Bendamustine Lymphoma Study Group.

Int J Hematol. 2017 Apr;105(4):470-477. doi: 10.1007/s12185-016-2146-4. Epub 2016 Nov 29.

PMID:
27900638
38.

Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan.

Ninomiya H, Obara N, Chiba S, Usuki K, Nishiwaki K, Matsumura I, Shichishima T, Okamoto S, Nishimura JI, Ohyashiki K, Nakao S, Ando K, Kanda Y, Kawaguchi T, Nakakuma H, Harada D, Akiyama H, Kinoshita T, Ozawa K, Omine M, Kanakura Y.

Int J Hematol. 2016 Nov;104(5):548-558. Epub 2016 Jul 27.

PMID:
27464489
39.

Clinical features and outcomes of patients with primary myelofibrosis in Japan: report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan.

Takenaka K, Shimoda K, Uchida N, Shimomura T, Nagafuji K, Kondo T, Shibayama H, Mori T, Usuki K, Azuma T, Tsutsumi Y, Tanaka J, Dairaku H, Matsuo K, Ozawa K, Kurokawa M, Arai S, Akashi K.

Int J Hematol. 2017 Jan;105(1):59-69. doi: 10.1007/s12185-016-2102-3. Epub 2016 Oct 19.

PMID:
27761702
40.

Aplastic anemia.

Usuki K.

Rinsho Ketsueki. 2016;57(10):1890-1899. Japanese.

PMID:
27725585
41.

Acute Myeloid Leukemia-associated Charcot-Leyden Crystals in the Bone Marrow.

Nashiro T, Hashimoto H, Horiuchi H, Usuki K.

Intern Med. 2016;55(13):1821-2. doi: 10.2169/internalmedicine.55.6368. Epub 2016 Jul 1. No abstract available.

42.

Clinical characteristics and prognosis of acute myeloid leukemia associated with DNA-methylation regulatory gene mutations.

Ryotokuji T, Yamaguchi H, Ueki T, Usuki K, Kurosawa S, Kobayashi Y, Kawata E, Tajika K, Gomi S, Kanda J, Kobayashi A, Omori I, Marumo A, Fujiwara Y, Yui S, Terada K, Fukunaga K, Hirakawa T, Arai K, Kitano T, Kosaka F, Tamai H, Nakayama K, Wakita S, Fukuda T, Inokuchi K.

Haematologica. 2016 Sep;101(9):1074-81. doi: 10.3324/haematol.2016.143073. Epub 2016 May 31.

43.

Repeat courses of SRS in patients initially treated with SRS alone for brain-metastatic melanoma.

Bates JE, Youn P, Usuki KY, Dhakal S, Milano MT.

Melanoma Manag. 2016 Jun;3(2):97-104. doi: 10.2217/mmt-2016-0005. Epub 2016 May 25.

44.

[Clinical analysis of chronic myeloid leukemia patients complicated with chronic kidney impairment during treatment with tyrosine kinase inhibitors].

Ando Y, Hangaishi A, Saika M, Chizuka A, Kida M, Usuki K.

Rinsho Ketsueki. 2016 Mar;57(3):340-5. doi: 10.11406/rinketsu.57.340. Japanese.

PMID:
27076247
45.

Prognostic significance of Wilms tumor 1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes.

Kobayashi S, Ueda Y, Nannya Y, Shibayama H, Tamura H, Ogata K, Akatsuka Y, Usuki K, Ito Y, Okada M, Suzuki T, Hata T, Matsuda A, Tohyama K, Kakumoto K, Koga D, Mitani K, Naoe T, Sugiyama H, Takaku F.

Cancer Biomark. 2016 Mar 31;17(1):21-32. doi: 10.3233/CBM-160612.

PMID:
27062571
46.

Decision Analysis of Postremission Therapy in Cytogenetically Intermediate-Risk Acute Myeloid Leukemia: The Impact of FLT3 Internal Tandem Duplication, Nucleophosmin, and CCAAT/Enhancer Binding Protein Alpha.

Kurosawa S, Yamaguchi H, Yamaguchi T, Fukunaga K, Yui S, Wakita S, Kanamori H, Usuki K, Uoshima N, Yanada M, Shono K, Ueki T, Mizuno I, Yano S, Takeuchi J, Kanda J, Okamura H, Inamoto Y, Inokuchi K, Fukuda T.

Biol Blood Marrow Transplant. 2016 Jun;22(6):1125-1132. doi: 10.1016/j.bbmt.2016.03.015. Epub 2016 Mar 31.

47.

Spectrum of clinical and genetic features of patients with inherited platelet disorder with suspected predisposition to hematological malignancies: a nationwide survey in Japan.

Yoshimi A, Toya T, Nannya Y, Takaoka K, Kirito K, Ito E, Nakajima H, Hayashi Y, Takahashi T, Moriya-Saito A, Suzuki K, Harada H, Komatsu N, Usuki K, Ichikawa M, Kurokawa M.

Ann Oncol. 2016 May;27(5):887-95. doi: 10.1093/annonc/mdw066. Epub 2016 Feb 15.

PMID:
26884589
48.

Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review.

Miyasaka N, Miura O, Kawaguchi T, Arima N, Morishita E, Usuki K, Morita Y, Nishiwaki K, Ninomiya H, Gotoh A, Imashuku S, Urabe A, Shichishima T, Nishimura J, Kanakura Y.

Int J Hematol. 2016 Jun;103(6):703-12. doi: 10.1007/s12185-016-1946-x. Epub 2016 Feb 8. Review.

PMID:
26857155
49.
50.

Severe radiation-induced leukoencephalopathy: Case report and literature review.

Cummings M, Dougherty DW, Mohile NA, Walter KA, Usuki KY, Milano MT.

Adv Radiat Oncol. 2016 Feb 2;1(1):17-20. doi: 10.1016/j.adro.2016.01.002. eCollection 2016 Jan-Mar. No abstract available.

Supplemental Content

Support Center